T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.81B |
| 2 |
Boeing
BA
|
+$1.68B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$1.33B |
| 4 |
Amphenol
APH
|
+$1.11B |
| 5 |
CME Group
CME
|
+$902M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$3.65B |
| 2 |
Advanced Micro Devices
AMD
|
+$2.51B |
| 3 |
UnitedHealth
UNH
|
+$2.06B |
| 4 |
Uber
UBER
|
+$1.84B |
| 5 |
Adobe
ADBE
|
+$1.44B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.21% |
| 2 | Healthcare | 12.77% |
| 3 | Consumer Discretionary | 11.71% |
| 4 | Financials | 11.15% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2876
Alta Equipment Group
ALTG
$252M
| $69K | ﹤0.01% |
+10,463
| New | +$72.9K |
|
2877
Compass Therapeutics
CMPX
$412M
| $69K | ﹤0.01% |
46,942
+11,326
| +32% | +$18.8K |
|
2878
Lexeo Therapeutics
LXEO
$398M
| $69K | ﹤0.01% |
+10,425
| New | +$82.1K |
|
2879
ProKidney
PROK
$306M
| $69K | ﹤0.01% |
40,478
+5,073
| +14% | +$9.15K |
|
|
SUP
2880
DELISTED
Superior Industries International
SUP
| $69K | ﹤0.01% |
33,700
| – | – |
|
2881
Veru
VERU
$46.2M
| $69K | ﹤0.01% |
10,611
| – | – |
|
2882
Biote Corp
BTMD
$44.2M
| $67K | ﹤0.01% |
+10,709
| New | +$62.2K |
|
2883
Cardiff Oncology
CRDF
$79.4M
| $67K | ﹤0.01% |
15,390
-33,847
| -69% | -$106K |
|
2884
W&T Offshore
WTI
$539M
| $67K | ﹤0.01% |
39,829
+7,776
| +24% | +$15.5K |
|
2885
Evolution Petroleum
EPM
$135M
| $65K | ﹤0.01% |
+12,259
| New | +$67.1K |
|
2886
Tango Therapeutics
TNGX
$4.32B
| $65K | ﹤0.01% |
20,998
+4,813
| +30% | +$22.3K |
|
2887
Beam Global
BEEM
$25.5M
| $63K | ﹤0.01% |
19,600
| – | – |
|
2888
Perspective Therapeutics
CATX
$363M
| $63K | ﹤0.01% |
19,692
+1,784
| +10% | +$14.6K |
|
2889
Dakota Gold
DC
$819M
| $63K | ﹤0.01% |
28,317
+6,416
| +29% | +$14.5K |
|
2890
Destination XL Group
DXLG
$34.8M
| $63K | ﹤0.01% |
23,334
+7,020
| +43% | +$18.9K |
|
2891
Fate Therapeutics
FATE
$310M
| $63K | ﹤0.01% |
38,049
-27,170
| -42% | -$68.5K |
|
2892
AlTi Global
ALTI
$462M
| $61K | ﹤0.01% |
13,674
+2,807
| +26% | +$11.9K |
|
|
KYNB
2893
Kyntra Bio
KYNB
$28.7M
| $61K | ﹤0.01% |
4,640
-1,620
| -26% | -$15.1K |
|
2894
Larimar Therapeutics
LRMR
$450M
| $60K | ﹤0.01% |
15,452
+1,992
| +15% | +$13.1K |
|
2895
Nkarta
NKTX
$171M
| $60K | ﹤0.01% |
23,958
+7,030
| +42% | +$21.7K |
|
2896
Rackspace Technology
RXT
$1.14B
| $60K | ﹤0.01% |
26,807
+5,214
| +24% | +$13.2K |
|
2897
Gossamer Bio
GOSS
$85.5M
| $59K | ﹤0.01% |
64,777
-6,369,269
| -99% | -$5.46M |
|
|
HSHP
2898
Himalaya Shipping
HSHP
$737M
| $59K | ﹤0.01% |
+12,131
| New | +$79.4K |
|
2899
CS Disco
LAW
$285M
| $59K | ﹤0.01% |
+11,724
| New | +$68.1K |
|
2900
Puma Biotechnology
PBYI
$458M
| $59K | ﹤0.01% |
19,083
+5,726
| +43% | +$16.7K |
|
Similar funds
T. Rowe Price Associates's Q4 2024 Portfolio in Review
As of Q4 2024, T. Rowe Price Associates held 3,110 positions worth $867B, down 0.13% from $869B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
T. Rowe Price Associates's Q4 2024 filing shows 92 new, 1,805 increased, 946 reduced and 96 closed positions. Its largest new stake was South Bow Corp: 12,337,055 shares worth $291M. The largest sale was Apple, an estimated $3.65B.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2024 buy was South Bow Corp: 12,337,055 shares worth $291M.
- T. Rowe Price Associates added most to Broadcom in Q4 2024, an estimated $2.81B increase.
- T. Rowe Price Associates's biggest Q4 2024 reduction was Apple, cutting an estimated $3.65B.
- T. Rowe Price Associates fully exited Tempus AI in Q4 2024, selling an estimated $292M.
- T. Rowe Price Associates's ten largest holdings make up 35% of its $867B portfolio in Q4 2024.
- T. Rowe Price Associates opened 92 new positions and closed 96 in Q4 2024.
- T. Rowe Price Associates's portfolio value fell 0.13% quarter-over-quarter to $867B.
Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.